Management of chemotherapy-induced neutropenia: Measuring quality, cost, and value

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 1, 2015, Pages e1-e7

  Dinan, Michaela A ^a,b   Hirsch, Bradford R ^a,b   Lyman, Gary H ^c,d  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR;

ARTICLE; CANCER CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); PATIENT CARE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; ECONOMICS; STANDARDS;

CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COLONY-STIMULATING FACTORS; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; HEALTH CARE COSTS; HUMANS; PATIENT CARE; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE;

EID: 84921457586     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0014     Document Type: Article

References (41)

1. Schnipper LE, Meropol NJ, Brock DW. Value and cancer care: toward an equitable future. Clinical cancer research: an official journal of the American Association for Cancer Research 2010;16:6004-6008.
2. Ramsey S, Schickedanz A. How should we define value in cancer care? Oncologist 2010;15(Suppl 1):1-4.
3. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-4198.
4. Garber A, Goldman DP, Jena AB. The promise of health care cost containment. Health Aff (Millwood) 2007;26:1545-1547.
5. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14:1165-1174.
6. Keating NL, Landrum MB, Lamont EB, et al. Area-level variations in cancer care and outcomes. Med Care 2012;50:366-373.
7. Porter ME. What is value in health care? N Engl J Med 2010;363:2477-2481.
8. Hoverman J. Relating value in cancer care to cost and outcome. Oncology Business Review 2011;5:24-26.
9. Lyman GH. Counting the costs of cancer care. Lancet Oncol 2013;14:1142-1143.
10. Porter ME, Teisberg EO. How physicians can change the future of health care. JAMA 2007;297:1103-1111.
11. Liu L, Rettenmaier AJ, Saving TR. Comparative effectiveness and comparative costs. Oncology (Williston Park) 2010;24:537.
12. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996;14:671-679.
13. Lyman GH. Comparative effectiveness research in oncology. Oncologist 2013;18:752-759.
14. Konski A. Cost, quality, and value in healthcare: a new paradigm. Oncology (Williston Park) 2010;24:542-543.
15. Feeley TW, Fly HS, Albright H, et al. A method for defining value in healthcare using cancer care as a model. Journal of healthcare management / American College of Healthcare Executives 2010;55:399-411.
16. Schnipper LE, Lyman GH, Blayney DW, et al. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol 2013;31:4362-4370.
17. Ramsey SD, Sullivan SD, Reed SD, et al. Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting. Oncologist 2013;18:760-767.
18. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266.
19. Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400-411.
20. Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004:CD003189.
21. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-3167.
22. Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1:23-35.
23. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32.
24. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205.
25. Crawford J, Becker PS, Armitage J, et al. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. Version 2, 2014. Available at: NCCN.org. Accessed January 8, 2014.
26. Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440-454.
27. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl 1):1-15.
28. Filgrastim label information. Dailymed Web site. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193. Accessed January 9, 2014.
29. Amgen 2011 Earnings Report. Availalbe at: http://www.amgen.com/media/media-pr-detail.jsp?releaseID=1653300. Accessed January 24, 2014.
30. Doorduijn JK, Buijt I, van der Holt B, et al. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2004;89:1109-1117.
31. Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy 2009;7:193-205.
32. Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172-179.
33. Hirsch BR, Lyman GH. Will biosimilars gain momentum? J Natl Compr Canc Netw 2013;11:1291-1297.
34. Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129-146.
35. Smith TJ. Economic analysis of the clinical uses of the colony-stimulating factors. Curr Opin Hematol 1996;3:175-179.
36. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-4531.
37. Numnum TM, Kimball KJ, Rocconi RP, et al. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma - a cost-effectiveness analysis. Int J Gynecol Cancer 2007;17:1019-1024.
38. Fust K, Li X, Maschio M, et al. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. Gynecol Oncol 2014;133:446-453.
39. Michels SL, Barron RL, Reynolds MW, et al. Costs associated with febrile neutropenia in the US. Pharmacoeconomics 2012;30:809-823.
40. Renner P, Milazzo S, Liu JP, et al. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev 2012;10:CD007913.
41. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013;24:2475-2485.